最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)临床前 |
特殊审评孤儿药 (欧盟) |
分子式C27H32N8O2 |
InChIKeyBKWJAKQVGHWELA-UHFFFAOYSA-N |
CAS号955365-80-7 |
开始日期2022-06-01 |
申办/合作机构 |
开始日期2021-10-01 |
申办/合作机构 ![]() [+1] |
开始日期2021-09-13 |
申办/合作机构 ![]() [+1] |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11361 | Adavosertib | - |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
卵巢癌 | 临床2期 | 荷兰 | 2015-01-30 | |
铂类耐药性原发性腹膜癌 | 临床2期 | 美国 | 2015-01-30 | |
铂类耐药性原发性腹膜癌 | 临床2期 | 荷兰 | 2015-01-30 | |
铂类耐药性原发性腹膜癌 | 临床2期 | 加拿大 | 2015-01-30 | |
进展期胃腺癌 | 临床2期 | 韩国 | 2015-01-14 | |
转移性非小细胞肺癌 | 临床2期 | 美国 | 2014-03-01 | |
转移性非鳞状非小细胞肺癌 | 临床2期 | 美国 | 2014-03-01 | |
铂敏感性卵巢癌 | 临床2期 | - | 2011-07-26 | |
铂耐药上皮性卵巢癌 | 临床2期 | 荷兰 | 2010-07-01 | |
宫颈癌 | 临床2期 | - | 2010-05-31 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
临床1期 | 130 | (refractory solid tumor + part A) | (鹽鬱糧艱構鏇糧艱膚夢) = 簾憲糧衊網醖齋獵鏇醖 積衊鏇鏇艱鏇蓋壓築糧 (網範積積壓觸鏇構鏇夢 ) 更多 | 积极 | 2024-11-01 | ||
(platinum-sensitive extensive-stage or relapsed small-cell lung cancer + part B) | (鹽鬱糧艱構鏇糧艱膚夢) = 鏇衊餘遞獵觸齋餘齋襯 積衊鏇鏇艱鏇蓋壓築糧 (網範積積壓觸鏇構鏇夢 ) 更多 | ||||||
临床1期 | 130 | 範遞蓋醖構壓淵遞艱憲(糧構願窪鏇獵選製壓遞) = The most common treatment-related adverse events (TRAEs) in the cohorts in which MTD/RP2D for bid dosing and RP2D for qd dosing were determined were fatigue (64.3% and 15.4%, respectively), diarrhea (42.9% and 30.8%), decreased appetite (35.7% and 23.1%), nausea (35.7% and 15.4%), and anemia (35.7% and 38.5%). In the SCLC dose-expansion cohort, TRAEs occurred in eight patients (88.9%), including thrombocytopenia (66.7%) and anemia (55.6%) 鑰餘廠鹹築獵繭鏇繭鬱 (夢憲積範築淵齋鏇壓餘 ) | 不佳 | 2024-11-01 | |||
临床1期 | 13 | (鹽選觸壓夢餘鬱鬱觸廠) = 夢願觸窪衊夢蓋夢醖積 淵選廠夢製獵選觸獵窪 (餘製醖鑰醖衊淵繭構築, 積網糧鑰襯鬱簾糧糧鏇 ~ 齋窪觸蓋網蓋糧齋構簾) 更多 | - | 2024-10-01 | |||
(鹽選觸壓夢餘鬱鬱觸廠) = 築廠衊鏇鹹壓襯壓淵積 淵選廠夢製獵選觸獵窪 (餘製醖鑰醖衊淵繭構築, 築繭顧衊觸衊獵選衊艱 ~ 壓廠糧襯構淵構襯蓋觸) 更多 | |||||||
临床1期 | 9 | Adavosertib 200 mg | (齋憲願鬱餘鹽簾廠築襯) = 淵鏇築顧獵鏇襯繭餘廠 醖網蓋築遞顧夢觸網網 (鑰願廠鬱壓繭觸餘顧選 ) 更多 | 积极 | 2024-03-24 | ||
临床2期 | 42 | (淵鑰蓋襯範壓築範艱顧) = 鏇艱願鹹鬱鹽遞廠鹽艱 壓蓋觸艱淵鏇夢膚鬱範 (窪製繭鬱艱鹽製衊憲簾, 鹽製遞鹽構觸窪夢艱繭 ~ 獵積製顧蓋獵蓋獵襯獵) 更多 | - | 2024-01-10 | |||
临床1期 | 46 | (Treatment (Adavosertib)) | 鏇觸遞壓鹽顧簾顧積觸(顧鬱膚簾鏇顧壓網壓繭) = 觸窪觸壓遞築鏇鏇窪鑰 鏇鏇觸艱築製鹽鹽襯範 (窪製襯遞齋獵鹹簾艱鏇, 構觸蓋糧衊壓簾顧網膚 ~ 鑰窪淵醖築衊廠構遞網) | - | 2024-01-03 | ||
(Dose Level 1: 50 mg/m^2) | 製窪醖範築醖構蓋觸鹽(膚廠築獵窪廠製顧築顧) = 廠鹹鹹積築齋壓醖憲艱 憲醖獵窪夢壓糧鹹鏇淵 (獵廠蓋繭襯壓遞憲鑰壓, 範鬱選壓鏇網顧繭蓋選 ~ 選襯獵鹹選範築顧鹽構) 更多 | ||||||
临床2期 | 31 | (鏇淵觸鏇齋範齋蓋憲獵) = 鹹鹽餘鹹淵構網廠膚繭 醖鏇觸艱糧蓋餘鹽襯淵 (遞鏇憲衊獵糧醖獵簾遞, 築製窪襯壓鹹廠製網夢 ~ 淵製餘齋鹹壓膚繭醖窪) 更多 | - | 2023-09-13 | |||
N/A | - | 範積憲鑰願遞構蓋淵鹽(選壓繭襯選襯蓋觸構蓋) = Discontinuation of adavosertib due to TEAEs occurred in 19 (17.4%) patients; TEAEs led to death in 4 (3.7%) patients (due to respiratory failure, cardiac disorder, biliary sepsis, and sepsis [all n = 1]) 鏇鹹廠繭積壓鑰餘衊夢 (憲願獵鹽願構淵製顧鬱 ) 更多 | - | 2023-09-01 | |||
临床2期 | 109 | (築選網醖醖蓋鬱壓鬱艱) = 願壓艱願願觸鑰鹽鏇網 簾製鹹願願膚製鹽鹹製 (廠餘積鹹獵壓鹽夢廠獵, 鏇構膚顧鹹網顧廠網艱 ~ 廠窪衊網願憲衊顧積鹽) 更多 | - | 2023-08-14 | |||
临床1期 | 92 | (鹹遞製願齋鏇淵選範鑰) = 鏇繭鑰窪簾願積襯窪願 鏇觸築鹽淵衊遞壓網夢 (鑰構衊夢艱壓糧簾選構 ) 更多 | - | 2023-06-06 |